Navigation Links
Instrumentation Laboratory Receives FDA Clearance for New Automated Total Bilirubin Assay on GEM Premier 4000 Critical Care Analyzer
Date:7/27/2010

ANAHEIM, Calif., July 27 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced that it has received clearance from the US Food and Drug Administration (FDA) to market the first-ever, rapid point-of-care, lab-quality blood test for measuring total bilirubin (tBili) in newborns.  

Bilirubin, a toxin, can, in high amounts, lead to irreversible brain injury in neonates.  The new tBili assay is performed on IL's GEM Premier 4000 critical care analyzer.  It allows clinicians to receive lab-quality test results in 90 seconds from whole blood in the Neonatal Intensive Care Unit (NICU), rather than waiting up to an hour for results from the lab, using traditional chemistry methods.    

During the first few days of life, the body breaks down fetal red blood cells, producing bilirubin.  More bilirubin is produced than the liver can remove, and it remains circulating in the blood.  This results in jaundice, the most common condition requiring medical attention in newborns, present in approximately 70%.  However, in 8-10% of newborns, jaundice progresses to severe hyperbilirubinemia.  Left untreated, hyperbilirubinemia can quickly evolve into kernicterus, a devastating, irreversible neonatal brain injury.  

"Over the past decade, kernicterus has reemerged, due to a variety of factors," said Anthony Napolitano, M.D., a Neonatologist, Medical Director, Neonatal/Pediatric Transport Program at All Children's Hospital, St. Petersburg, FL and Medical Director, Sarasota Memorial Hospital, Sarasota, FL.  "The ability to assess bilirubin in the NICU with accuracy and precision is a tremendous advantage and has the potential to prevent this absolutely devastating outcome and reduce hospital readmissions."

The American Academy of Pediatrics recommends that a risk-assessment for bilirubin be performed on every newborn to reduce the incidence of adverse events.

"Now, with the addition of the tBili assay to the GEM Premier 4000 analyzer, screening can be performed immediately, with the highest quality results assured," said Ramon Benet, VP of US Sales and Worldwide Service and Marketing at IL.  "No other analyzer can provide lab-quality tBili results in the NICU."

tBili assays performed on the GEM Premier 4000 are not affected by moderate turbidity or hemolysis, ensuring accuracy.  Additionally, from a single whole blood sample, a full range of analytes can be measured, including Blood Gas, Electrolytes, Glucose, Lactate and full CO-Oximetry, for an efficient and comprehensive assessment of patient status.

"At IL, we are intensely focused on continuously improving our products to enhance patient care," Benet added.  "Helping clinicians to eradicate kernicterus and detect rising tBili early, while still treatable, is a very gratifying outcome of our efforts."

IL announced the FDA clearance of the tBili assay at the Annual Meeting of the American Association for Clinical Chemistry in Anaheim, California.  At the meeting, IL also introduced GEMweb Plus Custom Connectivity, software for automated information management.  GEMweb Plus is the only software to provide system-wide, bi-directional capabilities from any networked PC of GEM Premier 4000 analyzer.  GEMweb Plus provides complete control of all networked analyzers, regardless of location, to enhance quality assurance and regulatory compliance.

About Kernicterus – a Devastating "Never Event"

The National Quality Forum, a consensus standards-setting organization dedicated to improving the quality of healthcare in the US, considers kernicterus one of twenty-eight "Never Events," defined as "adverse events that are serious, largely preventable" and considered "inexcusable outcomes in a healthcare setting."  Unfortunately, over the past decade, the US has seen a re-emergence of kernicterus, believed to be linked to lapses in care and accuracy of testing.  

About GEM Premier 4000

GEM® Premier™ 4000 critical care analyzer provides blood gas, electrolyte and metabolite analysis with integrated CO-Oximetry testing.  It features IL's patented Intelligent Quality Management (iQM®), a real-time, automated, quality assurance system that continuously detects, corrects and documents, to assure quality results and compliance, 24/7, regardless of operator or testing location.  iQM, coupled with its cartridge-based technology and ease of use, allows the GEM Premier 4000 analyzer to provide consistent, accurate, lab-quality results throughout the hospital.

Instrumentation Laboratory (www.ilus.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories.  The company's product lines include critical care systems, hemostasis systems and information management systems.  IL's GEM® product offerings, part of the critical care line, include the new GEM Premier 3500 with Intelligent Quality Management (iQM®), GEM Premier™ 4000 analyzer, GEMweb Plus Custom Connectivity, and the GEM PCL Plus, a portable coagulation analyzer.  IL's hemostasis portfolio includes the ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, including the ACL TOP 700, the new ACL TOP 700 LAS and the ACL TOP 500 CTS.  IL also offers the new ACL AcuStar™, ACL ELITE® and ELITE PRO, other hemostasis analyzers and the HemosIL® line of reagents.  IL is based in Bedford, Massachusetts.

The Instrumentation Laboratory logo, GEM, iQM, HemosIL, ACL TOP, ACL ELITE, ACL AcuStar and Premier are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions.  All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.


'/>"/>
SOURCE Instrumentation Laboratory
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Instrumentation Laboratory Achieves Record Sales in 2009
2. Patient-Specific Surgical Instrumentation Expedites Total Knee Replacement Procedures
3. Instrumentation Laboratory Receives 510(K) Clearance From FDA and Canadian License for HemosIL(R) D-Dimer HS 500 Assay
4. Amerinet Awards Contract to Instrumentation Laboratory for Critical Care Portfolio
5. Instrumentation Laboratory Installs 2000th ACL TOP(R) System
6. Instrumentation Laboratory Receives FDA Clearance for HemosIL RecombiPlasTin 2G Assay
7. CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests
8. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
9. OvaGene Oncology Opens New Innovative Gynecologic Cancer Laboratory and Research Facility
10. Dominion Diagnostics Introduces CARD™: The Next-Generation Clinical Laboratory Diagnostics Tool for Addiction Treatment
11. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... MOUNTAIN VIEW, Calif. , Dec. 8, 2016 ... it intends to offer newly issued shares of common stock, ... "Shares") pursuant to an underwritten public offering.  The final terms ... at the time of pricing, and there can be no ... completed. IRIDEX expects to use the net proceeds ...
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)...  The global biosurgery market is expected to grow ... of 2016 to 2021. The market is poised to ... billion in 2016. The market is primarily driven by ... injuries and spinal problems, increasing clearance of biosurgery products ... loss management. In this report, the biosurgery ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa Wound ... Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the ... hospitals and facilities have earned this distinction. This is the second time the ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the ... series, and attorneys from the firm’s global Life Sciences & Medical Technology Group have ...
Breaking Medicine News(10 mins):